A Phase 1/2 interventional study of NMS-01940153E in Unresectable Hepatocellular Carcinoma (HCC), sponsored by Nerviano Medical Sciences. Terminated at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-19.
Sponsored by Nerviano Medical Sciences · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Carcinoma, Hepatocellular with a site in Italy — 49 open to participants now, 74 under way, 12 of them phase 3. Carcinoma, Hepatocellular · Italy.
Among the 206 studies in Carcinoma, Hepatocellular with a site in Italy, this one is the 124th largest by enrollment of the 144 interventional ones that give a count, is one of 6 that started in 2020, is one of 14 in phase 1/2, and was the 150th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →49 of the 206 studies in Carcinoma, Hepatocellular with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy
Ages 18–100
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18–64
CatalYm GmbH · Sites in Italy, United States, France and 4 more countries
Ages 18–100
Bristol-Myers Squibb · Sites in Italy, United States, Australia and 11 more countries
Ages 18+
Niguarda Hospital · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 52 · Phase 3 49 · Phase 4 3
First in 1998; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 156 across the 144 interventional studies, 200 across the 60 observational. Of the 116 that completed or were terminated, 48 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
115 of 206 have an industry lead sponsor. The 10 most frequent:
Nerviano Medical Sciences is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
Nerviano Medical Sciences has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
15 of the studies in Carcinoma, Hepatocellular with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04523493Phase 3Shanghai Junshi Bioscience Co., Ltd.Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT05911633Terumo Europe N.V.BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) | 2026-11-30 |
Add all 15 to your calendar (.ics) → With an account.
Among the 206 studies in Carcinoma, Hepatocellular with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I/II, open-label, non-randomized, multicenter study to explore safety, tolerability and antitumor activity of NMS-01940153E as single agent in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.
The Phase I portion is designed as a dose-escalation study in sequential cohorts of patients aimed to obtain the maximum tolerated dose (MTD) that is defined based on the dose limiting toxicities (DLTs) observed in the first cycle of treatment.
The Phase II portion is designed as a two-stage study with an interim analysis for futility and stopping criteria for unacceptable toxicity to assess the antitumor activity of NMS-01940153E in adult patients with unresectable HCC previously treated with systemic therapy measured as objective response rate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
Exclusion Criteria:
The presence of any of the following will exclude a subject from study enrollment:
Ascites defined as Grade ≥2. Subjects who have been on a stable medication regimen for at least 2 months to manage ascites are eligible if they show ascites Grade \<2.
Subjects with clinically undetectable ascites who are Child A with detectable ascites at CT/MRI are eligible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I: Patients will be allocated to sequential cohorts of progressively higher dose levels of NMS-01940153E based on the presence of Dose Limiting Toxicities (DLT). Phase II: Patients will be treated at the recommended Phase II dose (RP2D) defined in the Phase I portion.
Drug: NMS-01940153E
Route of administration: intravenous (IV) solution
Phase I Drug Related Dose Limiting Toxicities (DLTs)
All 12 Phase I treated patients were evaluable for DLT (Dose-Limiting Toxicity Evaluable Set) and included 6 patients treated at each of the two dose levels explored (i.e., 100 mg/m2/week and 135 mg/m2/week) who received at least 66% of the study drug in the first 28-day cycle of treatment and underwent a DLT assessment within the DLT window. Participants who experienced DLTs are presented.
Time frame: Phase I: From screening to end of first 28-day cycle (17 months)
Phase II Objective Response Rate
The objective response rate (ORR) was calculated as the proportion of evaluable patients who achieved, as best overall response (BOR), confirmed complete response (CR) or partial response (PR) measured by investigator-assessed RECIST 1.1 (Phase II).
Time frame: Phase II: From Phase II start to Study Completion (23 months)
Treatment-emergent Adverse Events by Maximum CTC Grade
The maximum Common Terminology Criteria (CTC) grade (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)
Treatment-emergent Adverse Events Related to NMS-01940153E
The number of treatment-emergent adverse events related to NMS-01940153E by maximum CTC grade experienced (graded using NCI CTCAE Version 5.0). Whether the the AE was related or not was assessed by the investigator. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening. Phase 2 started before Phase 1 completed.
Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)
Hematology: Overall Treatment-emergent Abnormalities by Dose Level and Maximum CTC Grade
Number of treatment emergent abnormalities (at any grade) at all dose levels are presented. CTC = Common Terminology Criteria WBC = white blood cells
Time frame: From screening to 28 days follow-up, an average 6 months
Neutrophils Count Decrease: Time to First Occurrence of >=Grade 3 and Time to Recovery to Grade 1
The mean days to first occurrence of neutrophil count decrease are presented for all dose levels. Grade 0: ≥2,000/mm3 Grade 1: ≥1,500-\< 2,000/mm3 Grade 2: ≥1,000- \< 1,500/mm3 Grade 3: ≥500- \< 1,000/mm3 Grade 4: \<500/mm3 * G3 = Time (days) to Treatment Start to First Occurrence of Neutrophil Count Decrease \>=Grade 3 * G3 to Recovery to G1 = Time (days) to First Occurrence of Neutrophil Count Decrease \>= Grade 3 to Recovery to Grade 1
Time frame: From screening to 28 days follow-up, an average 6 months
Blood Chemistry: Treatment-emergent Abnormalities by Dose Level
Treatment-emergent abnormalities in blood chemistry at any grade are presented by dose level. ALP = Alkaline phosphatase ALT = Alanine aminotransferase AST = Aspartate aminotransferase GGT = Gamma-glutamyl transferase LDH = Lactate dehydrogenase
Time frame: From screening to 28 days follow-up, an average 6 months
Blood Chemistry and Coagulation: Treatment-emergent Abnormalities
Treatment Emergent abnormalities by dose Level are presented for blood chemistry and coagulation parameters. INR = international normalized ratio LNL = lower normal limit NL = normal limit ULN = upper limit of normal
Time frame: From screening to 28 days follow-up, an average 6 months
Electrocardiogram Abnormalities
The number of participants who experienced electrocardiogram abnormalities are presented.
Time frame: From screening to 28 days follow-up, an average 6 months
Tmax and Tlast of NMS-01940153E
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Tmax = Time to maximum observed plasma concentration Tlast = Time of last detectable concentration
Time frame: Day 1 to Day 15
Cmax and Clast of NMS-01940153E
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Cmax = Maximum observed plasma concentration Clast = Last detectable concentration
Time frame: Day 1 to Day 15
AUClast, AUCweekly, and AUCinf of NMS-01940153E
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. AUClast = Area under the interpolated observed plasma time-concentration curve from infusion start to the last observed plasma concentration AUCweekly = Area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours AUCinf = Area under the interpolated observed plasma time-concentration curve from infusion start extrapolated to infinity based on the last observed plasma concentration
Time frame: From Days 1 to 21 (168 hours after the Day 15 infusion)
t½,z of NMS-01940153E
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. t½,z = Half-life of the terminal phase of observed plasma concentration
Time frame: Day 1 to Day 15
CL and CLss of NMS-01940153E
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. CL = Clearance based on last observed concentration and extrapolation to infinity CLss = Clearance calculated for a dosing period of 168 h either after a single dose or in steady-state
Time frame: Day 1 to Day 15
Vss and Vss,SS of NMS-01940153E
Plasma pharmacokinetic (PK) PK profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Vss = Volume of distribution at steady state based last observed concentration extrapolated to infinity and Clearance calculated for a dosing period of 168 h either after a single dose or in steady-state Vss,SS = Volume of distribution at steady state based last observed concentration extrapolated to infinity and clearance based on last observed concentration and extrapolation to infinity
Time frame: Day 1 to Day 15
RA AUCweekly and RA Cmax of NMS-01940153E
Plasma pharmacokinetic (PK) PK profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. RA AUCweekly = Accumulation ratio Day 1 to 15 calculated using area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours RA Cmax = Accumulation ratio Day 1 to 15 calculated using maximum observed plasma concentration
Time frame: Day 21 (168 hours after the Day 15 infusion)
FE of NMS-01940153E
Urine pharmacokinetic profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. FE = Molar fraction of excreted compound relative to the administered molar dose calculated using urine concentration and volume data
Time frame: Day 1 to Day 15
Phase I Objective Tumor Response (Partial and Complete Response)
Phase I any dose level, objective response and best overall tumor response are presented, as measured by investigator assessed RECIST 1.1 (Phase I). The objective response rate was calculated as the proportion of evaluable patients who achieved best overall response (BOR), confirmed complete response (CR) or partial response (PR).
Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months)
Phase II Objective Response Rate as Measured by Investigator-assessed mRECIST
Objective response rate as measured by investigator-assessed mRECIST in Phase II.
Time frame: Phase II: From Phase II start to Study Completion (23 months)
Phase I: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.1
Duration of response (DoR) as measured by investigator-assessed Response evaluation criteria in solid tumours (RECIST) 1.1. Duration of Response (months): was time in months from response start date to either date of disease progression/death due to progression of disease. It was calculated only for participants with complete response or partial response as best overall response.
Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months)
Phase II: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.1. and Investigator-assessed mRECIST
Duration of response (DoR) as measured by investigator-assessed Response evaluation criteria in solid tumours (RECIST) 1.1 and investigator-assessed modified RECIST (mRECIST). Duration of Response (months): was time in months from response start date to either date of disease progression/death due to progression of disease. It was calculated only for participants with complete response or partial response as best overall response.
Time frame: Phase II: From Phase II start to Study Completion (23 months)
Progression Free Survival, as Measured by Investigator-assessed RECIST 1.1, in Phases I and II
Progression Free Survival as measured by investigator assessed RECIST 1.1, for all treated participants in Phase I and Phase II. Phase 2 started before Phase 1 completed.
Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)
Overall Survival in Phases I and II
Overall Survival for all treated participants in Phases I and II. The estimates are based on the Kaplan-Meier (KM) method. Phase 2 started before Phase 1 completed.
Time frame: Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months)
| Milestone | Phase 1 Participants: 100 mg/m2/Week | Phase I Participants: 135 mg/m2/Week | Phase II Participants: 100 mg/m2/Week | Enrolled But Not Treated |
|---|---|---|---|---|
| Started | 6 | 6 | 18 | 1 |
| Completed | 5 | 5 | 9 | 0 |
| Not completed | 1 | 1 | 9 | 1 |
| Withdrew: Study terminated by sponsor | 1 | 1 | 8 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Enrolled but not treated | 0 | 0 | 0 | 1 |
All 12 Phase I treated patients were evaluable for DLT (Dose-Limiting Toxicity Evaluable Set) and included 6 patients treated at each of the two dose levels explored (i.e., 100 mg/m2/week and 135 mg/m2/week) who received at least 66% of the study drug in the first 28-day cycle of treatment and underwent a DLT assessment within the DLT window. Participants who experienced DLTs are presented.
| Participants | 100 mg/m2/Week Dose (Phase I) | 135 mg/m2/Week Dose (Phase I) |
|---|---|---|
| Phase I Drug Related Dose Limiting Toxicities (DLTs) | 0 | 2 |
The objective response rate (ORR) was calculated as the proportion of evaluable patients who achieved, as best overall response (BOR), confirmed complete response (CR) or partial response (PR) measured by investigator-assessed RECIST 1.1 (Phase II).
| Participants | Phase II (Evaluable Population) |
|---|---|
| Stable Disease | 3 |
| Progressive Disease | 11 |
| Complete Response | 0 |
| Partial Response | 0 |
The maximum Common Terminology Criteria (CTC) grade (graded using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
| Participants | 100 mg/m2/Week Dose (Phase I) | 135 mg/m2/Week Dose (Phase I) | Phase II (Evaluable Population) |
|---|---|---|---|
| Grade 1 | 0 | 0 | 3 |
| Grade 2 | 1 | 1 | 8 |
| Grade 3 | 3 | 3 | 7 |
| Grade 4 | 1 | 2 | 0 |
The number of treatment-emergent adverse events related to NMS-01940153E by maximum CTC grade experienced (graded using NCI CTCAE Version 5.0). Whether the the AE was related or not was assessed by the investigator. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening. Phase 2 started before Phase 1 completed.
| events | 100 mg/m2/Week Dose (Phase I) | 135 mg/m2/Week Dose (Phase I) | Phase II (Evaluable Population) |
|---|---|---|---|
| Grade 1 | 0 | 0 | 7 |
| Grade 2 | 1 | 1 | 3 |
| Grade 3 | 2 | 2 | 2 |
| Grade 4 | 1 | 2 | 0 |
Number of treatment emergent abnormalities (at any grade) at all dose levels are presented. CTC = Common Terminology Criteria WBC = white blood cells
| events | 100 mg/m2/Week Dose (Phase I and II) | 135 mg/m2/Week Dose (Phase I Only) | All Treated Participants (Phase I and II; All Dose Levels) |
|---|---|---|---|
| Hemoglobin Decreased | 13 | 5 | 18 |
| Neutrophil Count Decreased | 6 | 4 | 10 |
| WBC Decreased | 8 | 6 | 14 |
| Platelet Count Decreased | 6 | 4 | 10 |
The mean days to first occurrence of neutrophil count decrease are presented for all dose levels. Grade 0: ≥2,000/mm3 Grade 1: ≥1,500-\< 2,000/mm3 Grade 2: ≥1,000- \< 1,500/mm3 Grade 3: ≥500- \< 1,000/mm3 Grade 4: \<500/mm3 * G3 = Time (days) to Treatment Start to First Occurrence of Neutrophil Count Decrease \>=Grade 3 * G3 to Recovery to G1 = Time (days) to First Occurrence of Neutrophil Count Decrease \>= Grade 3 to Recovery to Grade 1
| days | 100 mg/m2/Week Dose (Phase I and II) | 135 mg/m2/Week Dose (Phase I Only) | All Treated Participants (Phase I and II; All Dose Levels) |
|---|---|---|---|
| >=G3 | 63.00 ± 19.80 | 28.00 ± 15.36 | 39.67 ± 23.38 |
| >= G3 to Recovery to G1 | 7.00 ± 1.41 | 7.33 ± 3.51 | 7.20 ± 2.59 |
Treatment-emergent abnormalities in blood chemistry at any grade are presented by dose level. ALP = Alkaline phosphatase ALT = Alanine aminotransferase AST = Aspartate aminotransferase GGT = Gamma-glutamyl transferase LDH = Lactate dehydrogenase
| events | 100 mg/m2/Week Dose (Phase I and II) | 135 mg/m2/Week Dose (Phase I Only) | All Treated Participants (Phase I and II; All Dose Levels) |
|---|---|---|---|
| Hypoalbuminemia | 8 | 4 | 12 |
| Hypoglycemia | 0 | 1 | 1 |
| AST Increased | 12 | 3 | 15 |
| ALT Increased | 8 | 2 | 10 |
| GGT Increased | 9 | 1 | 10 |
| Creatinine Increased | 6 | 3 | 9 |
| Blood Bilirubin Increased | 7 | 1 | 8 |
| ALP Increased | 10 | 1 | 11 |
| Blood LDH Increased | 14 | 4 | 18 |
| Hypocalcemia | 1 | 1 | 2 |
| Hypernatremia | 0 | 1 | 1 |
| Hyperkalemia | 7 | 0 | 7 |
| Hypomagnesemia | 5 | 3 | 8 |
Treatment Emergent abnormalities by dose Level are presented for blood chemistry and coagulation parameters. INR = international normalized ratio LNL = lower normal limit NL = normal limit ULN = upper limit of normal
| events | 100 mg/m2/Week Dose (Phase I and II) | 135 mg/m2/Week Dose (Phase I Only) | All Treated Participants (Phase I and II; All Dose Levels) |
|---|---|---|---|
| Hyponatremia: Total | 4 | 2 | 6 |
| Hyponatremia: Below LNL | 4 | 2 | 6 |
| Hypokalemia: Total | 0 | 1 | 1 |
| Hypokalemia: Below LNL | 0 | 1 | 1 |
| Phosphatemia: Total | 11 | 2 | 13 |
| Phosphatemia: Above ULN | 3 | 0 | 3 |
| Phosphatemia: Below LNL | 7 | 2 | 9 |
| Phosphatemia: Above/Below NL | 1 | 0 | 1 |
| Hyperglycemia: Total | 9 | 2 | 11 |
| Hyperglycemia: Above ULN | 9 | 1 | 10 |
| Hyperglycemia: Above/Below NL | 0 | 1 | 1 |
| Blood Urea Nitrogen: Total | 2 | 0 | 2 |
| Blood Urea Nitrogen: Above ULN | 2 | 0 | 2 |
| Urea: Total | 6 | 0 | 6 |
| Urea: Above ULN | 5 | 0 | 5 |
| Urea: Below LNL | 1 | 0 | 1 |
| Unconjugated Bilirubin: Total | 3 | 0 | 3 |
| Unconjugated Bilirubin: Above ULN | 3 | 0 | 3 |
| Total Protein: Total | 7 | 2 | 9 |
| Total Protein: Above ULN | 2 | 0 | 2 |
| Total Protein: Below LNL | 4 | 2 | 6 |
| Total Protein: Above/Below NL | 1 | 0 | 1 |
| INR: Total | 11 | 1 | 12 |
| INR: Above ULN | 8 | 1 | 9 |
| INR: Below LNL | 1 | 0 | 1 |
| INR: Above/Below NL | 2 | 0 | 2 |
The number of participants who experienced electrocardiogram abnormalities are presented.
| Participants | 100 mg/m2/Week Dose (Phase I) | 135 mg/m2/Week Dose (Phase I) | Phase II (Evaluable Population) |
|---|---|---|---|
| Electrocardiogram Abnormalities | 0 | 0 | 0 |
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Tmax = Time to maximum observed plasma concentration Tlast = Time of last detectable concentration
| hours | 100 mg/m2/Week Dose (Phase I Only) | 135 mg/m2/Week Dose (Phase I Only) |
|---|---|---|
| Tmax: Day 1 | 0.933 ± 0.0327 | 1.19 ± 0.513 |
| Tmax: Day 15 | 1.10 ± 0.216 | 1.87 ± 1.90 |
| Tlast: Day 1 | 169 ± 3.01 | 154 ± 39.2 |
| Tlast: Day 15 | 144 ± 48.5 | 169 ± 0.418 |
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Cmax = Maximum observed plasma concentration Clast = Last detectable concentration
| μM | 100 mg/m2/Week Dose (Phase I Only) | 135 mg/m2/Week Dose (Phase I Only) |
|---|---|---|
| Cmax: Day 1 | 0.754 ± 0.174 | 1.91 ± 0.640 |
| Cmax: Day 15 | 1.35 ± 1.10 | 1.59 ± 1.31 |
| Clast: Day 1 | 0.0590 ± 0.0191 | 0.0840 ± 0.0335 |
| Clast: Day 15 | 0.113 ± 0.0454 | 0.133 ± 0.0779 |
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. AUClast = Area under the interpolated observed plasma time-concentration curve from infusion start to the last observed plasma concentration AUCweekly = Area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours AUCinf = Area under the interpolated observed plasma time-concentration curve from infusion start extrapolated to infinity based on the last observed plasma concentration
| h·μM | 100 mg/m2/Week Dose (Phase I Only) | 135 mg/m2/Week Dose (Phase I Only) |
|---|---|---|
| AUClast: Day 1 | 20.8 ± 4.31 | 24.8 ± 8.55 |
| AUClast: Day 15 | 30.0 ± 9.16 | 39.1 ± 14.9 |
| AUCweekly: Day 1 | 20.8 ± 4.35 | 25.7 ± 7.11 |
| AUCweekly: Day 15 | 32.4 ± 6.49 | 39.0 ± 14.8 |
| AUCinf: Day 1 | 28.7 ± 6.88 | 37.1 ± 14.9 |
| AUCinf: Day 15 | 48.1 ± 19.6 | 62.9 ± 34.1 |
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. t½,z = Half-life of the terminal phase of observed plasma concentration
| days | 100 mg/m2/Week Dose (Phase I Only) | 135 mg/m2/Week Dose (Phase I Only) |
|---|---|---|
| t½,z Day 1 | 3.74 ± 0.800 | 4.17 ± 1.40 |
| t½,z Day 15 | 4.38 ± 2.64 | 4.79 ± 1.15 |
Plasma pharmacokinetic (PK) profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. CL = Clearance based on last observed concentration and extrapolation to infinity CLss = Clearance calculated for a dosing period of 168 h either after a single dose or in steady-state
| L/h | 100 mg/m2/Week Dose (Phase I Only) | 135 mg/m2/Week Dose (Phase I Only) |
|---|---|---|
| CL: Day 1 | 10.1 ± 3.16 | 10.2 ± 4.01 |
| CL: Day 15 | 6.12 ± 2.24 | 6.19 ± 2.08 |
| CLss: Day 1 | 13.8 ± 4.14 | 13.8 ± 3.73 |
| CLss: Day 15 | 8.53 ± 2.50 | 9.31 ± 2.52 |
Plasma pharmacokinetic (PK) PK profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Vss = Volume of distribution at steady state based last observed concentration extrapolated to infinity and Clearance calculated for a dosing period of 168 h either after a single dose or in steady-state Vss,SS = Volume of distribution at steady state based last observed concentration extrapolated to infinity and clearance based on last observed concentration and extrapolation to infinity
| L | 100 mg/m2/Week Dose (Phase I Only) | 135 mg/m2/Week Dose (Phase I Only) |
|---|---|---|
| Vss: Day 1 | 1230 ± 395 | 1210 ± 199 |
| Vss: Day 15 | 787 ± 304 | 919 ± 245 |
| Vss,SS: Day 1 | 1700 ± 620 | 1630 ± 285 |
| Vss,SS: Day 15 | 1180 ± 649 | 1380 ± 354 |
Plasma pharmacokinetic (PK) PK profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. Infusions occurred on Days 1, 8, and 15. RA AUCweekly = Accumulation ratio Day 1 to 15 calculated using area under the interpolated observed plasma time-concentration curve from infusion start to 168 hours RA Cmax = Accumulation ratio Day 1 to 15 calculated using maximum observed plasma concentration
| ratio | 100 mg/m2/Week Dose (Phase I Only) | 135 mg/m2/Week Dose (Phase I Only) |
|---|---|---|
| RA AUCweekly: Day 15 | 1.66 ± 0.188 | 1.51 ± 0.293 |
| RA Cmax: Day 15 | 1.78 ± 1.36 | 0.858 ± 0.547 |
Urine pharmacokinetic profiles of NMS-01940153E were characterized on Day 1 and 15 of the first Cycle after infusion. FE = Molar fraction of excreted compound relative to the administered molar dose calculated using urine concentration and volume data
| percentage | 100 mg/m2/Week Dose (Phase I Only) | 135 mg/m2/Week Dose (Phase I Only) |
|---|---|---|
| FE Day 1 | 0.458 ± 0.374 | 0.357 ± 0.260 |
| FE Day 15 | 0.563 ± 0.424 | 0.826 ± 0.713 |
Phase I any dose level, objective response and best overall tumor response are presented, as measured by investigator assessed RECIST 1.1 (Phase I). The objective response rate was calculated as the proportion of evaluable patients who achieved best overall response (BOR), confirmed complete response (CR) or partial response (PR).
| Participants | 100 mg/m2/Week Dose (Phase I) | 135 mg/m2/Week Dose (Phase I) |
|---|---|---|
| Objective Response (Partial Response) | 1 | 1 |
| Objective Response (Complete Response) | 0 | 0 |
| Stable Disease | 1 | 2 |
| Progressive Disease | 4 | 2 |
Objective response rate as measured by investigator-assessed mRECIST in Phase II.
| Participants | Phase II Treated Participants |
|---|---|
| Stable Disease | 3 |
| Progressive Disease | 11 |
| Objective Response (Partial Response) | 0 |
| Objective Response (Complete Response) | 0 |
Duration of response (DoR) as measured by investigator-assessed Response evaluation criteria in solid tumours (RECIST) 1.1. Duration of Response (months): was time in months from response start date to either date of disease progression/death due to progression of disease. It was calculated only for participants with complete response or partial response as best overall response.
| months | 100 mg/m2/Week Dose (Phase I) | 135 mg/m2/Week Dose (Phase I) |
|---|---|---|
| Phase I: Duration of Response (DoR) as Measured by Investigator-assessed RECIST 1.1 | 2.6 | 9.3 |
Duration of response (DoR) as measured by investigator-assessed Response evaluation criteria in solid tumours (RECIST) 1.1 and investigator-assessed modified RECIST (mRECIST). Duration of Response (months): was time in months from response start date to either date of disease progression/death due to progression of disease. It was calculated only for participants with complete response or partial response as best overall response.
No measurements were reported for this outcome.
Progression Free Survival as measured by investigator assessed RECIST 1.1, for all treated participants in Phase I and Phase II. Phase 2 started before Phase 1 completed.
| months | 100 mg/m2/Week Dose (Phase I) | 135 mg/m2/Week Dose (Phase I) | Phase II (Evaluable Population) |
|---|---|---|---|
| Progression Free Survival, as Measured by Investigator-assessed RECIST 1.1, in Phases I and II | 1.9 (1.7 to 6.5) | 7.8 (1.8 to 25.1) | 1.9 (1.8 to 4.1) |
Overall Survival for all treated participants in Phases I and II. The estimates are based on the Kaplan-Meier (KM) method. Phase 2 started before Phase 1 completed.
| months | 100 mg/m2/Week Dose (Phase I) | 135 mg/m2/Week Dose (Phase I) | Phase II (Evaluable Population) |
|---|---|---|---|
| Overall Survival in Phases I and II | 9.7 (5.2 to NA) | 15.7 (4.7 to NA) | 7.3 (3.9 to NA) |
Collected over Phase I: From the Study Start Date to Phase I Completion (32 months) - Phase II: From Phase II start to Study Completion (23 months). Phase 2 started before Phase 1 completed.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I: 100 mg/m2/Week | 5/6 (83.3%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Phase I: 135 mg/m2/Week | 5/6 (83.3%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase II: 100 mg/m2/Week | 9/18 (50%) | 5/18 (27.8%) | 18/18 (100%) |
| Event | Phase I: 100 mg/m2/Week | Phase I: 135 mg/m2/Week | Phase II: 100 mg/m2/Week |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/6 | 1/6 | 0/18 |
| NeutropeniaBlood and lymphatic system disorders | 0/6 | 1/6 | 0/18 |
| SepsisInfections and infestations | 1/6 | 1/6 | 1/18 |
| Device related bacteraemiaInfections and infestations | 1/6 | 0/6 | 0/18 |
| Disease progressionGeneral disorders | 0/6 | 0/6 | 2/18 |
| Pathological fractureMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 1/18 |
| Device related infectionInfections and infestations | 0/6 | 0/6 | 1/18 |
| Peritonitis bacterialInfections and infestations | 0/6 | 0/6 | 1/18 |
| Event | Phase I: 100 mg/m2/Week | Phase I: 135 mg/m2/Week | Phase II: 100 mg/m2/Week |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 2/6 | 3/6 | 2/18 |
| Abdominal pain upperGastrointestinal disorders | 3/6 | 0/6 | 4/18 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 3/6 | 2/18 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/6 | 3/6 | 1/18 |
| AstheniaGeneral disorders | 1/6 | 1/6 | 8/18 |
| Infusion site reactionGeneral disorders | 1/6 | 2/6 | 3/18 |
| Oedema peripheralGeneral disorders | 2/6 | 1/6 | 1/18 |
| Non-cardiac chest painGeneral disorders | 2/6 | 0/6 | 0/18 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 2/6 | 1/18 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/6 | 2/6 | 2/18 |
All treated participants
| Age, Categorical(Participants) | Phase I Participants: 100 mg/m2/Week | Phase I Treated Participants: 135 mg/m2/Week | Phase II Participants: 100 mg/m2/Week | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 10 | 16 |
| >=65 years | 3 | 3 | 8 | 14 |
| Sex: Female, Male(Participants) | Phase I Participants: 100 mg/m2/Week | Phase I Treated Participants: 135 mg/m2/Week | Phase II Participants: 100 mg/m2/Week | Total |
|---|---|---|---|---|
| Female | 1 | 0 | 1 | 2 |
| Male | 5 | 6 | 17 | 28 |
| Race (NIH/OMB)(Participants) | Phase I Participants: 100 mg/m2/Week | Phase I Treated Participants: 135 mg/m2/Week | Phase II Participants: 100 mg/m2/Week | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 |
| White | 5 | 6 | 18 | 29 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Eastern cooperative oncology group performance status(participants) | Phase I Participants: 100 mg/m2/Week | Phase I Treated Participants: 135 mg/m2/Week | Phase II Participants: 100 mg/m2/Week | Total |
|---|---|---|---|---|
| ECOG Performance Status 0 | 3 | 3 | 10 | 16 |
| ECOG Performance Status 1 | 3 | 3 | 8 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2020 to primary completion in Jan 2024, 38 months.
Results were first posted in May 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nerviano Medical Sciences